Evolus Inc. (EOLS)

Name: Evolus Inc. (EOLS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Evolus Inc. (EOLS)

Stock Card

$8.88

$0.10 (1.14%)

As on 27-Aug-2026 16:00EDT

Market cap

$554 Mln

Revenue (TTM)

$316 Mln

P/E Ratio

P/B Ratio

53.7

Div. Yield

0 %

Evolus (EOLS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 8.60 High: 9.04

52 Week Range

Low: 3.86 High: 9.12

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-187.3 %
ROCE

-- %
Industry P/E

37.31
EV/EBITDA

-21.5
Debt to Equity

-5.1
Book Value

$--
EPS

$-0.5
Face value

--
Shares outstanding

66,050,440

9 Years Aggregate

CFO

$-315.78 Mln

EBITDA

$-413.67 Mln

Net Profit

$-538.48 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Evolus (EOLS)	33.5	48.5	42.1	16.1	-0.7	-3.8	--
BSE Sensex	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Evolus (EOLS)	-39.8	4.8	40.2	15.4	93.8	-72.4	2.3
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Evolus (EOLS)	8.9	554.2	316.5	-34.3	-4.2	--	--	53.7
Amneal Pharmaceuticals Inc Class A (AMRX)	18.0	6,238.0	3,117.6	157.4	14.7	--	37.3	188.9
Axsome Therapeutics (AXSM)	206.3	10,883.2	776.6	-191.6	-17.6	-223.4	--	130.9
BridgeBio Pharma (BBIO)	78.7	15,932.7	691.8	-696.2	-89.1	--	--	123.7
Corcept Therapeutics (CORT)	116.9	13,215.0	830.8	54.9	3.2	8.1	271.7	18.7
Dr. Reddy's Laboratories - ADR	12.2	10,087.6	332,834.2	33,166.6	11.1	8.9	28.8	2.5
Elanco Animal Health (ELAN)	24.5	11,971.8	5,020.0	-199.0	1.6	-3	--	1.8
Ligand Pharmaceuticals (LGND)	284.5	5,707.4	290.5	197.2	82.5	19.9	29.6	5.9
Liquidia Technologies Inc (LQDA)	69.9	6,142.1	450.9	138.6	39.1	115.6	49	31.5
Twist Bioscience Corp (TWST)	153.1	9,129.6	431.8	-136.7	-30.8	-30.3	--	20.5

Shareholding Pattern

View Details

About Evolus (EOLS)

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the... temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Read more

President, CEO & Director

Mr. David Moatazedi
President, CEO & Director

Mr. David Moatazedi
Headquarters

Newport Beach, CA
Website

https://www.evolus.com

FAQs for Evolus (EOLS)

What is the current share price of Evolus Inc (EOLS) Today?

The share price of Evolus Inc (EOLS) is $8.88 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Evolus Inc (EOLS) has given a return of -0.67% in the last 3 years.

What is the current PB & PE ratio of Evolus Inc (EOLS)?

Since, TTM earnings of Evolus Inc (EOLS) is negative, P/E ratio is not available.
The P/B ratio of Evolus Inc (EOLS) is 53.71 times as on 21-Aug-2026, a 593 premium to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.